Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 9/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2294331 | 0.83 | PDE10A (0.47) | DRD3SLC6A3PDE10A | |
| SCHEMBL14945573 | 0.83 | PDE10A (0.47) | DRD3SLC6A3PDE10A | |
| SCHEMBL2298028 | 0.83 | PDE10A (0.47) | DRD3SLC6A3PDE10A | |
| SCHEMBL2743213 | 0.75 | CYP2D6 (0.52) | DRD3CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL13257724 | 0.75 | CYP2D6 (0.52) | DRD3CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL16510079 | 0.75 | CYP2D6 (0.52) | DRD3CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL25259107 | 0.74 | CYP2D6 (0.38) | DRD3CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL10747371 | 0.74 | PDE10A (0.46) | DRD3CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL12919984 | 0.73 | HPGD (0.44) | DRD3CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL16465230 | 0.73 | DRD3 (0.48) | DRD3CHRM2HTR1AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7994166-B2 | Pyrrolidinone benzenesulfonamide derivatives as modulators of ion channels for the treatment of pain | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-08-09 | — | — | US | disclosed |
| US-20090131440-A1 | HETEROCYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131440-A1 | HETEROCYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS | TRPV1, KCNJ2, KCNN3 | DRD3 2222/4885CYP2D6 1652/4885SLC6A2 460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.